Design of Enzyme Inhibitors as Drugs

Introduction to the use of enzyme inhibitors as drugs; general approaches to the design of inhibitors; inhibitors of the Renin-Angiotens in system enzymes; lactamase inhibitors; enkephalinase inhibitors as drugs; monoamine oxidase inhibitors; polyamine oxidase inhibitors; new developments in enzyme activated irreversible inhibitors of pyridoxal phosphate-dependent enzymes of therapeutic interest; cholinesterase and esterase inhibitors and reactivators of organophosphorus-inhibited esterases; inhibitors of enzymes of the arachidonic acid metabolic pathways; selective inhibitors of dihydrofolate reductases; the antibacterial sulphonamides; inhibitors of enzymes of the de novo pyrimidine pathway; inhibitors of purine biosynthesis; inhibitors of Na+, K+ ATpase; inhibitors of steriod biosynthesis; inhibitions of enzymes involved in bacterial cell wall synthesis; inhibition of proteinases; development of selective inhibitors of calmodulin-dependent phosphodiesterase and adenylate cyclase; inhibitors of carbonic anhydrase; inhibition of intracellular methyl transfer and aminopropyl transfer reactions by analogues of substrates, products, and transition states; inhibitors of some other target enzymes as potential clinical agents. Index.